Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.

MLA

Kwon, Christina S., et al. “Cost-Effectiveness Analysis of Metformin+dipeptidyl Peptidase-4 Inhibitors Compared to Metformin+sulfonylureas for Treatment of Type 2 Diabetes.” BMC Health Services Research, vol. 18, no. 1, Feb. 2018, p. 78. EBSCOhost, https://doi.org/10.1186/s12913-018-2860-0.

APA

Kwon, C. S., Seoane-Vazquez, E., & Rodriguez-Monguio, R. (2018). Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes. BMC Health Services Research, 18(1), 78. https://doi.org/10.1186/s12913-018-2860-0

Chicago

Kwon, Christina S, Enrique Seoane-Vazquez, and Rosa Rodriguez-Monguio. 2018. “Cost-Effectiveness Analysis of Metformin+dipeptidyl Peptidase-4 Inhibitors Compared to Metformin+sulfonylureas for Treatment of Type 2 Diabetes.” BMC Health Services Research 18 (1): 78. doi:10.1186/s12913-018-2860-0.